Bristol-myers Squibb Compnay

Swanee E Jacutin-Porte

John E Macor

Guanglin Luo

Gene Michael Dubowchik

Prasanna Sivaprakasam

Ling Chen

Pratik Devasthale

Guohua Zhao

Michael Frederick Parker

Xiaojun Han

Rita Civiello

Xiang-Yang Ye

Kumaravel Selvakumar

Suresh Dhanusu

Leatte R Guernon

Palanikumar Balasubramanian

Annapurna Pendri

Shoshana L Posy

Richard A Hartz

Vivekananda M Vrudhula

Vijay T Ahuja

Haibo Liu

Senliang Pan

Laura Akullian D'Agostino

Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.

Inhibitors of protein tyrosine phosphatase, compositions, and methods of use

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

GSK-3 inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. 

Substituted pyridine derivatives useful as GSK-3 inhibitors

Growing community of inventors

Madison, CT, United States of America

Swanee E Jacutin-Porte